JP2006519209A - ネモルビシン（ｎｅｍｏｒｕｂｉｃｉｎ）の肝臓内投与により肝臓癌を治療するための方法 - Google Patents
ネモルビシン（ｎｅｍｏｒｕｂｉｃｉｎ）の肝臓内投与により肝臓癌を治療するための方法 Download PDFInfo
- Publication number
- JP2006519209A JP2006519209A JP2006502019A JP2006502019A JP2006519209A JP 2006519209 A JP2006519209 A JP 2006519209A JP 2006502019 A JP2006502019 A JP 2006502019A JP 2006502019 A JP2006502019 A JP 2006502019A JP 2006519209 A JP2006519209 A JP 2006519209A
- Authority
- JP
- Japan
- Prior art keywords
- nemorubicin
- liver
- mcg
- use according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 title claims abstract description 50
- 229950010159 nemorubicin Drugs 0.000 title claims abstract description 49
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 25
- 201000007270 liver cancer Diseases 0.000 title abstract description 12
- 238000000034 method Methods 0.000 title description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 210000004185 liver Anatomy 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 18
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 210000002767 hepatic artery Anatomy 0.000 claims description 10
- 206010027476 Metastases Diseases 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 8
- 230000009401 metastasis Effects 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 abstract description 3
- 238000011269 treatment regimen Methods 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 description 26
- 230000004044 response Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 206010027457 Metastases to liver Diseases 0.000 description 7
- 229940045799 anthracyclines and related substance Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 210000005163 right hepatic lobe Anatomy 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 4
- 229960000961 floxuridine Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 201000002364 leukopenia Diseases 0.000 description 3
- 231100001022 leukopenia Toxicity 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011521 systemic chemotherapy Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DSXDXWLGVADASF-QQFKZXDBSA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-4-[(2s)-2-methoxymorpholin-4-yl]-6-methyloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 DSXDXWLGVADASF-QQFKZXDBSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229950010538 irinotecan hydrochloride trihydrate Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- -1 methoxymorpholino group Chemical group 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03100470 | 2003-02-26 | ||
| PCT/EP2004/050112 WO2004075904A1 (en) | 2003-02-26 | 2004-02-11 | Method for treating liver cancer by intrahepatic administration of nemorubicin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006519209A true JP2006519209A (ja) | 2006-08-24 |
| JP2006519209A5 JP2006519209A5 (enExample) | 2007-03-01 |
Family
ID=32921607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502019A Pending JP2006519209A (ja) | 2003-02-26 | 2004-02-11 | ネモルビシン（ｎｅｍｏｒｕｂｉｃｉｎ）の肝臓内投与により肝臓癌を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060264388A1 (enExample) |
| EP (1) | EP1596874B1 (enExample) |
| JP (1) | JP2006519209A (enExample) |
| AT (1) | ATE366579T1 (enExample) |
| DE (1) | DE602004007491T2 (enExample) |
| ES (1) | ES2289483T3 (enExample) |
| TW (1) | TW200501967A (enExample) |
| WO (1) | WO2004075904A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010526790A (ja) * | 2007-05-11 | 2010-08-05 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | アンスラサイクリンの医薬組成物 |
| JP2011516565A (ja) * | 2008-04-10 | 2011-05-26 | ヴァージニア コモンウェルス ユニバーシティ | 癌治療用腫瘍低酸素の誘発 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100464783C (zh) * | 2004-11-22 | 2009-03-04 | 山东蓝金生物工程有限公司 | 一种含抗肿瘤抗生素的抗癌药物组合物 |
| FR2992863B1 (fr) | 2012-07-06 | 2014-08-29 | Chu De Dijon | Composition pharmaceutique pour le traitement du cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015203A2 (en) * | 1998-09-14 | 2000-03-23 | Pharmacia & Upjohn S.P.A. | Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
| WO2000066093A2 (en) * | 1999-04-29 | 2000-11-09 | Pharmacia & Upjohn S.P.A. | Combined preparations comprising morpholine anthracyclines and anticancer agent |
-
2004
- 2004-02-11 US US10/546,234 patent/US20060264388A1/en not_active Abandoned
- 2004-02-11 ES ES04710040T patent/ES2289483T3/es not_active Expired - Lifetime
- 2004-02-11 AT AT04710040T patent/ATE366579T1/de not_active IP Right Cessation
- 2004-02-11 DE DE602004007491T patent/DE602004007491T2/de not_active Expired - Lifetime
- 2004-02-11 EP EP04710040A patent/EP1596874B1/en not_active Expired - Lifetime
- 2004-02-11 WO PCT/EP2004/050112 patent/WO2004075904A1/en not_active Ceased
- 2004-02-11 JP JP2006502019A patent/JP2006519209A/ja active Pending
- 2004-02-24 TW TW093104565A patent/TW200501967A/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015203A2 (en) * | 1998-09-14 | 2000-03-23 | Pharmacia & Upjohn S.P.A. | Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
| WO2000066093A2 (en) * | 1999-04-29 | 2000-11-09 | Pharmacia & Upjohn S.P.A. | Combined preparations comprising morpholine anthracyclines and anticancer agent |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010526790A (ja) * | 2007-05-11 | 2010-08-05 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | アンスラサイクリンの医薬組成物 |
| JP2011516565A (ja) * | 2008-04-10 | 2011-05-26 | ヴァージニア コモンウェルス ユニバーシティ | 癌治療用腫瘍低酸素の誘発 |
| JP2015110602A (ja) * | 2008-04-10 | 2015-06-18 | ヴァージニア コモンウェルス ユニバーシティ | 癌治療用腫瘍低酸素の誘発 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004007491D1 (de) | 2007-08-23 |
| ATE366579T1 (de) | 2007-08-15 |
| EP1596874B1 (en) | 2007-07-11 |
| DE602004007491T2 (de) | 2008-03-13 |
| WO2004075904A1 (en) | 2004-09-10 |
| ES2289483T3 (es) | 2008-02-01 |
| EP1596874A1 (en) | 2005-11-23 |
| TW200501967A (en) | 2005-01-16 |
| US20060264388A1 (en) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2307867T3 (es) | Preparacion combinada que comprende un derivado de morfolinil antraciclina y un inhibidor de topoisomerasa ii. | |
| RU2401662C2 (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| ES2441593T3 (es) | Composiciones para estimular la actividad de terapias anticáncer | |
| JP2014088398A (ja) | 肝臓腫瘍治療へのアントラサイクリン誘導体の使用 | |
| JP2019513812A (ja) | 化学療法の改善 | |
| Weinländer et al. | Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil | |
| KR20060126548A (ko) | (ａ) ＤＮＡ 토포이소머라제 억제제 및 (ｂ) ＩＡＰ 억제제조합물 | |
| JP2006519209A (ja) | ネモルビシン（ｎｅｍｏｒｕｂｉｃｉｎ）の肝臓内投与により肝臓癌を治療するための方法 | |
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| EP1771174A1 (en) | Method for treating abnormal cell growth | |
| Gadgeel et al. | A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration “2B” design | |
| KR20190039325A (ko) | 혈관차단제로 유용한 벤조페논 티아졸 유도체 및 토포이소머라제 억제제를 포함하는 암의 예방 또는 치료용 약학적 조합물 | |
| KR20220002745A (ko) | 암 치료 방법 및 용도 | |
| HK1050853B (en) | Use of methoxymorpholino doxorubicin in the preparation of a medicament for the treatment of a liver tumor | |
| BRPI0718021A2 (pt) | Uso de mtki 1 para tratar ou prevenir câncer ósseo | |
| WO2001058490A1 (en) | Liver-selective chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070110 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070110 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20080908 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20091208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100426 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100726 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100802 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100826 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100902 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101026 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110111 |